1 |
Khasraw M, Bell D, Wheeler H (2009). Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci, 16, 854-5.
DOI
|
2 |
Liang HJ, Yan YL, Liu ZM, et al (2013). Association of XRCC3 Thr241Met polymorphisms and gliomas risk: evidence from a meta-analysis. Asian Pac J Cancer Prev, 14, 4243-7.
DOI
ScienceOn
|
3 |
National Cancer Institute. CTCAE v3.0. Available at http://www.cancer.gov (accessed on 9 August 2006).
|
4 |
Ohgaki H, Kleihues P (2009). Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci, 100, 2235-41.
DOI
|
5 |
Qian ZZ, Wang HQ, Liu XM, et al (2009). [A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma]. Zhonghua Yi Xue Za Zhi, 89, 2059-62. Chinese.
|
6 |
Quinn JA1, Jiang SX, Reardon DA, et al (2009). Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol, 95, 393-00.
DOI
|
7 |
Reardon DA, Herndon JE, II, Peters K, et al (2011). Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol, 107, 213-21.
|
8 |
Santoni M, Paccapelo A, Burattini L, Onofri A, Cascinu S (2012). Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. Anticancer Res, 32, 1099-01.
|
9 |
Strik HM, Marosi C, Kaina B, et al (2012). Temozolomide dosing regimens for glioma patients. Curr Neurol Neurosci Rep, 12, 286-93.
DOI
|
10 |
Shen D, Yang QY, Chen ZP (2012). [Advances in the chemotherapy of malignant gliomas with temozolomide]. Chin J Neurooncol, 4, 271-6. Chinese.
|
11 |
Shen D, Yang QY, Chen ZP. Advances in the chemotherapy of malignant gliomas with temozolomide. Chin J Neurooncol, 4, 271-6. Chinese.
|
12 |
Silvani A, Lamperti E, Gaviani P, et al (2008). Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol, 87, 143-51.
DOI
|
13 |
Stupp R, Dietrich PY, Kraljevic S, et al (2002). Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol, 20, 1375-82.
DOI
ScienceOn
|
14 |
Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. J Clin Oncol, 25, 4127-36.
DOI
ScienceOn
|
15 |
Stupp R, Hegi ME, Mason WP, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol, 10, 459-66.
DOI
|
16 |
Stupp R, Mason WP, van den Bent MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987-96.
DOI
ScienceOn
|
17 |
Stupp R, Mason WP, van den Bent MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987-96.
DOI
ScienceOn
|
18 |
Tosoni A1, Franceschi E, Ermani M, et al (2008). Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol, 89, 179-85.
DOI
|
19 |
Wang YX, Fan K, Tao DB, et al (2013). Association between genetic polymorphism of xrcc1 gene and risk of Glioma in? Chinese population. Asian Pac J Cancer Prev, 14, 5957-60.
DOI
ScienceOn
|
20 |
Verhoeff JJ, Lavini C, van Linde ME, et al (2010). Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol, 21, 1723-7.
DOI
|
21 |
Vredenburgh JJ, Desjardins A, Herndon JE, II, et al (2007). Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol, 25, 4722-29
DOI
ScienceOn
|
22 |
Walker MD, Green SB, Byar DP, et al (1980). Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med, 303, 1323-9.
DOI
ScienceOn
|
23 |
Yan YI, Tang WY, Deng ZX, et al (2007). [Efficacy of temozolomide in treatment of recurrent glioma]. Cancer Res Prev Treat, 17, 1359-64. Chinese.
|
24 |
Yang P, Wang Y, Peng X, et al (2013). Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol, 113, 259-66.
DOI
|
25 |
Yu CY, Liang GB, Du P, et al (2013). Lgr4 promotes glioma cell proliferation through activation of Wnt signaling. Asian Pac J Cancer Prev, 14, 4907-11.
DOI
ScienceOn
|
26 |
Zhou LF, Wang RZ, Bao SD, et al (2012). Chinese guideline for diagnosis and treatment on central nervous system tumors. Zhonghua Yi Xue Za Zhi, 92, 2309-13.
|
27 |
Zhu Y, Zhuang JX, Wang Q, et al (2013). Inhibitory effect of benzyl isothiocyanate on proliferation in vitro of human glioma cells. Asian Pac J Cancer Prev, 14, 2607-10.
DOI
|
28 |
Brandes AA, Tosoni A, Cavallo G, et al (2006) .Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer, 95, 1155-60.
DOI
|
29 |
Zustovich F1, Lombardi G, Della Puppa A, et al (2009). A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. Anticancer Res, 29, 4275-9.
|
30 |
Zwinkels H, Roon K, Jeurissen FJ, et al (2009). Management of temozolomide toxicity by nurse practitioners in neurooncology. Oncol Nurs Forum, 36, 225-31.
DOI
|
31 |
Gaviani P, Salmaggi A, Silvani A (2008). Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients. J Neurooncol, 104, 617-18.
|
32 |
Athanassiou H, Synodinou M, Maragoudakis E, et al (2005). Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol, 23, 2372-7.
DOI
|
33 |
Chen C, Xu T, Lu Y, et al (2013). The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol, 20, 223-30.
DOI
|
34 |
Cheng HB, Xie C, Zhang RY, et al (2013). Xeroderma pigmentosum complementation group f polymorphisms influence risk of glioma. Asian Pac J Cancer Prev, 14, 4083-7.
DOI
ScienceOn
|
35 |
Ge YF, Sun J, Jin CJ, et al (2013). AntagomiR-27a targets FOXO3a in glioblastoma and suppresses U87 cell growth in vitro and in vivo. Asian Pac J Cancer Prev, 14, 963-8.
DOI
ScienceOn
|
36 |
Luo KQ, Mu SQ, Wu ZX, et al (2013). Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev, 14, 449-52.
DOI
ScienceOn
|
37 |
Jiang J, Quan XF, Zhang L, et al (2013). The XRCC3 Thr241Met polymorphism influences glioma risk - a meta-analysis. Asian Pac J Cancer Prev, 14, 3169-73.
DOI
|